A Perspective on the Kinetics of Covalent and Irreversible Inhibition
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2017/01/01
-
Journal
-
Indian UGC (journal)
-
Refrences141
-
Citations189
-
John M. Strelow
Article Updates
-
DOITypeTime
Cite
Strelow, John M. “A Perspective on the Kinetics of Covalent and Irreversible Inhibition”. SLAS Discovery, vol. 22, no. 1, 2017, pp. 3-20, https://doi.org/10.1177/1087057116671509.
Strelow, J. M. (2017). A Perspective on the Kinetics of Covalent and Irreversible Inhibition. SLAS Discovery, 22(1), 3-20. https://doi.org/10.1177/1087057116671509
Strelow JM. A Perspective on the Kinetics of Covalent and Irreversible Inhibition. SLAS Discovery. 2017;22(1):3-20.
Journal Categories
Medicine
Medicine (General)
Science
Biology (General)
Science
Chemistry
Analytical chemistry
Science
Chemistry
Organic chemistry
Biochemistry
Technology
Chemical technology
Biotechnology
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles | Journal of Biological Chemistry |
| 2016 | |
| Recent progress on third generation covalent EGFR inhibitors | Bioorganic & Medicinal Chemistry Letters |
| 74 | 2016 |
| High-Throughput Mass Spectrometric Analysis of Covalent Protein-Inhibitor Adducts for the Discovery of Irreversible Inhibitors: A Complete Workflow | SLAS Discovery |
| 35 | 2016 |
Designing Irreversible Inhibitors—Worth the Effort? | ChemMedChem |
| 57 | 2016 |
| Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants | Journal of Medicinal Chemistry |
| 69 | 2016 |
Refrences Analysis
The category
Science: Biology (General) 71
is the most frequently represented among the references in this article. It primarily includes studies from Journal of Medicinal Chemistry The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Discovery of a septin-4 covalent binder with antimetastatic activity in a mouse model of melanoma | Bioorganic Chemistry |
| 2024 | |
| Covalent hits and where to find them | SLAS Discovery |
| 2024 | |
| Computational Investigation of the Covalent Inhibition Mechanism of Bruton’s Tyrosine Kinase by Ibrutinib | Journal of Chemical Information and Modeling |
| 2024 | |
| Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization | Journal of Medicinal Chemistry |
| 2024 | |
| Fitting of kinact and KI Values from Endpoint Pre-incubation IC50 Data | ACS Medicinal Chemistry Letters |
| 2024 |
Citations Analysis
The category
Medicine: Therapeutics. Pharmacology 88
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Mechanistic enzymology in drug discovery: a fresh perspective and was published in 2017. The most recent citation comes from a 2024 study titled Targeting of REST with rationally-designed small molecule compounds exhibits synergetic therapeutic potential in human glioblastoma cells. This article reached its peak citation in 2022, with 43 citations. It has been cited in 87 different journals, 19% of which are open access. Among related journals, the Journal of Medicinal Chemistry cited this research the most, with 24 citations. The chart below illustrates the annual citation trends for this article.